Cjc-1295
CJC-1295 is a peptide designed to stimulate the pulsatile secretion of growth hormone (GH) through activation of the GHRH receptor. There are formulations with “Drug Affinity Complex” (DAC), which prolong the half-life through albumin binding, and variants without DAC with a shorter duration of action. The clinical literature is limited and mainly concerns endocrine biomarkers (GH/IGF-1) rather than long-term clinical outcomes.
GHRH (Growth Hormone-Releasing Hormone) analog peptide with a prolonged effect on the GH/IGF-1 axis
CJC-1295 is a peptide designed to stimulate the pulsatile secretion of growth hormone (GH) through activation of the GHRH receptor. There are formulations with “Drug Affinity Complex” (DAC), which extend the half-life through albumin binding, and variants without DAC with a shorter duration of action. The clinical literature is limited and mainly concerns endocrine biomarkers (GH/IGF-1) rather than long-term clinical outcomes.
Mechanism of action
Agonism of the GHRH receptor (GHRHR) at the level of pituitary somatotroph cells → increased pulsatile secretion of GH → increased hepatic (and peripheral) production of IGF-1 and modulation of protein synthesis, lipolysis, and metabolism. The formulation with DAC prolongs systemic exposure through albumin binding, maintaining a more sustained stimulus on the GH/IGF-1 axis compared with short half-life peptides.
Supported benefits
- Increase in circulating IGF-1 levels in adults (endocrine biomarker) (moderate)
- Increase in GH secretion (peak amplitude/frequency) under experimental conditions (moderate)
- Possible reduction in fat mass or changes in body composition (limited data, often indirect or not focused on robust clinical outcomes) (limited)
- Improvements in physical performance or recovery (direct human evidence is scarce; many claims derive from physiological extrapolations) (emerging)
Safety & side effects
- Injection site reactions (pain, redness, itching, nodules)
- Headache, flushing, nausea (reported in some experimental settings)
- Fluid retention/edema and paresthesias (possible with increased GH/IGF-1 signaling, especially if excessive)
- Alterations in blood glucose and insulin sensitivity (potential worsening of glycemic control in predisposed individuals)
- Possible increase in IGF-1 beyond physiological ranges with unpredictable long-term consequences
FAQ
Is CJC-1295 the same as GH (growth hormone)?
No. CJC-1295 is a GHRH analog: it stimulates the pituitary to release GH in a pulsatile manner. Exogenous GH is the hormone administered directly. The pharmacodynamic profiles and risks may differ.
What is the difference between CJC-1295 with DAC and without DAC?
The version with DAC is designed to bind to albumin and have a longer half-life (days), allowing less frequent regimens in studies. Variants without DAC have a shorter duration (hours) and require more frequent experimental protocols.
Does increasing IGF-1 automatically mean improved body composition or performance?
Not necessarily. An increase in IGF-1 is a biomarker of activation of the GH/IGF-1 axis, but clinical outcomes (strength, performance, metabolic health, quality of life) depend on many factors and have not been robustly demonstrated in healthy individuals.
What are the main theoretical risks of a chronic increase in IGF-1?
Possible effects on tissue growth, fluid retention, alterations in glucose metabolism and, in theory, modulation of proliferative processes. The long-term implications in healthy individuals are not well defined, but they require caution.
Are there dietary sources of CJC-1295?
No. It is a synthetic peptide; it is not naturally present in foods.
The information provided is for informational and educational purposes only. It does not constitute medical advice. Use must be evaluated and authorized by a qualified healthcare professional.
Mechanism of action
Agonism of the GHRH receptor (GHRHR) at the level of pituitary somatotroph cells → increased pulsatile GH secretion → increased hepatic (and peripheral) production of IGF-1 and modulation of protein synthesis, lipolysis, and metabolism. The formulation with DAC prolongs systemic exposure through albumin binding, maintaining a more sustained stimulus on the GH/IGF-1 axis compared with short half-life peptides.
Scientific benefits
Contraindications
- Active or suspected neoplasms (the IGF-1 signal is mitogenic and anti-apoptotic in several tissues; high caution advised)
- Acromegaly or conditions with excess GH/IGF-1
- Pregnancy and breastfeeding (insufficient data)
- Pediatric age outside specialist clinical settings (not appropriate in non-medical contexts)
- Uncontrolled diabetes or severe metabolic disorders (risk of worsening glycemic control)
Side effects
- Injection site reactions (pain, redness, itching, nodules)
- Headache, flushing, nausea (reported in some experimental contexts)
- Fluid retention/edema and paresthesias (possible with increased GH/IGF-1 signaling, especially if excessive)
- Changes in blood glucose and insulin sensitivity (potential worsening of glycemic control in predisposed subjects)
- Possible increase in IGF-1 beyond physiological ranges with unpredictable long-term consequences
Interactions
- Glucose-lowering drugs/insulin: possible need for clinical adjustments due to changes in blood glucose (interaction of potential relevance)
- Glucocorticoids: may antagonize some anabolic/metabolic effects of the GH axis and affect blood glucose
- Hormonal therapies (e.g. estrogens, thyroid hormones): may modulate the IGF-1 response and metabolism, altering the overall response
- Other GH secretagogues or exogenous GH: risk of excessive stimulation of the GH/IGF-1 axis and increased adverse events
Regulatory status
In many countries it is not approved as a medicinal product for general indications; it may appear as a “research only” product. In the sports context, it is typically included among substances prohibited by anti-doping regulations (category of GH-releasing factors/secretagogues). Legal and regulatory status varies by jurisdiction.
Supplements and peptides
PeptidesBpc-157
BPC-157 is a 15-amino-acid peptide derived from a sequence present in gastric juice (BPC). It is the subject of…
PeptidesDsip
DSIP (Delta Sleep-Inducing Peptide) is a peptide originally described for its possible ability to modulate sleep…
PeptidesEpitalon
Epitalon (often referred to as Epithalon) is a synthetic peptide composed of 4 amino acids (Ala-Glu-Asp-Gly), developed…